Another small study comparing fixed-dose oral mepolizumab with weight-based intravenous reslizumab showed greater improvements in airway eosinophilia and asthma control, with the notable observation that four of six mepolizumab non-responders had anti-EPX autoantibodies [110]. Here, EPX is linked to asthma.